- The study analyzes the different types of blood cells separately to identify signs of the disease that are difficult to detect using conventional methods
- The results open up a new avenue of research toward future blood biomarkers that will allow for minimally invasive monitoring of the disease
Alicante (September 7, 2026). Researchers from the Alicante Institute for Health and Biomedical Research (ISABIAL) and Miguel Hernández University in Elche have, for the first time, applied a molecular analysis involving single-cell RNA sequencing in blood to study Huntington’s disease.
This technique makes it possible to analyze blood cells individually to identify disease-related molecular abnormalities that may be difficult to detect using other analytical methods.
The study, published in the scientific journal *Scientific Reports*, was conducted through a collaboration between ISABIAL and the Institute for Research, Development, and Innovation in Health Biotechnology in Elche at Miguel Hernández University.
This strategy makes it possible to manage the cellular complexity of blood—which typically masks signs of this disease—and opens a new avenue for advancing the search for blood biomarkers that, in the future, may help monitor the disease’s progression in a minimally invasive way.
Huntington’s disease is a hereditary, highly debilitating, and fatal disorder. People living with the disease develop involuntary movements and abnormal body postures, as well as mental decline and, ultimately, death. This condition is caused by a mutation in the gene that produces the protein “huntingtin.”
The principal investigator of the ISABIAL research group on genetics, epigenetics, and transcription in neuropathologies and the study’s lead author, Luis M. Valor, points out that “while work continues to find an effective treatment, people who carry this mutation need specific tools to assess their actual condition, predict the onset of symptoms, and measure the progression of deterioration.”
Overcoming the Challenges of Blood Testing
Although blood tests are one of the most suitable methods for screening and monitoring because they are minimally invasive, the search for specific biomarkers for this disease presents significant challenges. This is due to natural variations among individuals—such as age, lifestyle, or genetic interactions—which mask the subtle changes associated with the disease that occur in the blood. Consequently, it is very difficult to develop a single, reliable blood test for any patient that can predict the progression and manifestation of the disease. To overcome this obstacle, the research team applied individualized analysis of blood cells, which facilitates the detection of the molecular alteration that indicates the disease’s status.
The study used mouse models to verify that the molecular changes detected in the blood accurately reflect brain damage. Despite differences between species, the team found a highly significant connection. They found that mice with poorer motor coordination exhibited high activity of the Irf7 gene, which plays a role in the body’s immune response and inflammation. Since Huntington’s disease causes constant inflammation in the brain, this gene appears to be overactivated.
“The most promising aspect of this study is that we detected this same molecular change in both the blood and the region of the brain most affected by Huntington’s,” says Valor. “This opens up the possibility that, in the future, a blood test could provide information on the progression of the disease without the need for more invasive tests.” The ISABIAL researcher notes that “these results from single-cell analysis complement previous studies aimed at identifying biomarkers in the blood to measure the onset and progression of the disease.”
Next Steps Toward Clinical Application
The researchers emphasize that these latest results have been obtained exclusively in animal models, so they are still far from being translated into a tool for clinical use. The next step will be to identify the genes whose link to Huntington’s disease is most robust in animal models. Validation in volunteers who meet the necessary statistical requirements will take place as part of a collaborative effort with various hospitals and research centers. If these results are confirmed in patients, they could contribute in the future to the development of blood tests capable of more accurately reflecting what is happening in the brain as the disease progresses.
In addition to ISABIAL researcher Luis Miguel Valor, the study’s authors include Paula Martín, a researcher at the University of Navarra and the Biomedical Research Network Center for the Pathophysiology of Obesity and Nutrition (CIBEROBN), part of the Carlos III Health Institute; ISABIAL researcher Samanta Ortuño; IDiBE UMH researcher Juan Gallego; and ISABIAL researcher Silvia Martí.
This scientific research was made possible thanks to financial support from various public institutions at the regional, national, and European levels. Specifically, the Carlos III Health Institute, the European Regional Development Fund, and the Ministry of Science and Innovation—NextGenerationEU.
Martín-Climent, P., Ortuño-Miquel, S., Gallego-Serna, J. F., Martí-Martínez, S., & Valor, L. M. (2026). Single-cell transcriptomics and mouse model phenotyping for biomarker screening of peripheral blood in Huntington’s disease. Scientific Reports. https://doi.org/10.1038/s41598-026-54412-4


